SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-023127
Filing Date
2023-08-10
Accepted
2023-08-10 17:05:51
Documents
69
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q vtgn20230630_10q.htm   iXBRL 10-Q 1144734
2 EXHIBIT 31.1 ex_555142.htm EX-31.1 8514
3 EXHIBIT 31.2 ex_555143.htm EX-31.2 8610
4 EXHIBIT 32 ex_555144.htm EX-32 4682
  Complete submission text file 0001437749-23-023127.txt   5390071

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230630.xsd EX-101.SCH 58113
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vtgn-20230630_cal.xml EX-101.CAL 35497
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230630_def.xml EX-101.DEF 380423
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230630_lab.xml EX-101.LAB 305180
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230630_pre.xml EX-101.PRE 402232
63 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230630_10q_htm.xml XML 660027
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37761 | Film No.: 231160544
SIC: 2834 Pharmaceutical Preparations